Citi Maintains on Intercept Pharmaceuticals

By: Benzinga
In a report published Friday, Citi analyst Yaron Werber maintained a Buy rating on Intercept Pharmaceuticals (NASDAQ: ICPT ), raising its price target from $60.00 to $400.00. According to the report, the new price target reflects a ~45 percent upside to yesterday's close. The increase is driven by the
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.